A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
A Phase Ib/II, Multicenter, Open-Label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors
Category & Conditions: Cancer
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
ClinicalTrials.gov Identifier (NCT): NCT01543698
Protocol ID: C4221005
PrintDownloadOpen Plain Language Summary Result: Click here